iCubate® to present on FDA-cleared iC-GPC Assay at SCACM conference

Huntsville, Ala. March 7, 2018 – iCubate®, Inc., an innovative molecular diagnostic device company, will host a workshop presentation at the South Central Association of Clinical Microbiology meeting in French Lick, Indiana. The presentation, “Providing Molecular Diagnostic Solutions One Cassette at a Time,” will be Thursday, March 8 at 10 am at the French Lick Resort, 8670 West State Street.

Among the items discussed will be the importance of timely, accurate results when detecting bloodstream infection, clinical laboratory requirements and iCubate’s recently cleared iC-GPC Assay™. The iC-GPC Assay is used for the rapid detection of pathogenic bacteria (gram-positive cocci) associated with bloodstream infections. In addition, attendees will have the opportunity to learn more about iCubate’s pipeline of products that will serve clinical laboratories.

iCubate’s FDA-cleared technology tests for multiple pathogens simultaneously from a single sample, simplifying the clinical workflow. The iC-GPC Assay is coupled with the iCubate System, which provides an easy to use, automated platform. The iC-System™ meets clinical laboratory needs and improves patient treatment through time-saving personalized diagnostics.

Presenting to the SCACM attendees will be Matthew Faron, PhD, instructor, clinical microbiology at the Medical College of Wisconsin; and Matthew Conover, PhD, assay developer and Molecular Biologist at iCubate.

“As someone who has been working with the iCubate system and iC-GPC Assay, I have first-hand knowledge of the performance and user experience”, said Dr. Faron. “I look forward to discussing my experience with iCubate at SCACM”.

Representatives from iCubate will also be available at the conference’s exhibit area, booth 220.

“Presenting at SCACM is an outstanding opportunity to showcase the iCubate technology and platform to those working each day in clinical laboratories. Our goal is to provide accurate, rapid results that ultimately impacts patient care in a positive way,”said Carter Wells, iCubate’s Chief Executive Officer.

The iC-GPC Assay™ is a multiplexed, in vitro diagnostic test for the identification of potentially pathogenic bacteria and clinically significant resistance markers, to aid in the diagnosis of bacterial bloodstream infections (BSI).

The iCubate platform and assay provides results up to 48 hours faster than conventional methods. The iC-GPC Assay™ provides identification of five of the most common gram positive organisms associated with gram positive bacteremia, including Staphylococcus aureus.  Additionally, the assay identifies three clinically relevant antibiotic resistance markers specific to methicillin resistant Staphylococcus and vancomycin resistant Enterococcus.

For further information about iCubate while attending SCACM, please contact Callie Spengler (callie.spengler@icubate.com256.327.0532 or 224.381.3293)

About iCubate®: iCubate®, Incorporated is a privately-held molecular diagnostic company located in the HudsonAlpha Institute for Biotechnology. iCubate’s mission is to provide a personal diagnosis that has an immediate and intelligent impact on patient lives. The integrated iCubate System (iC-System™) enables extraction, multiplexed amplification and detection automatically in a closed and disposable cassette. iCubate provides a sample-in answer-out diagnostic test with high multiplexing ARM-PCR technology in a user friendly, flexible platform. Other iCubate products are available world-wide for non-clinical, research-use only in the areas of health, agriculture, food safety and defense. See icubate.com for more information.

Forward-Looking Statements: Some statements in this press release may be “forward-looking statements”. iCubate® cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. iCubate undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.